More than 1 abnormality is a dominant characteristic of pure erythroid leukemia.
作者信息
Montalban-Bravo Guillermo, Benton Christopher B, Wang Sa A, Ravandi Farhad, Kadia Tapan, Cortes Jorge, Daver Naval, Takahashi Koichi, DiNardo Courtney, Jabbour Elias, Borthakur Gautam, Konopleva Marina, Pierce Sherry, Bueso-Ramos Carlos, Patel Keyur, Kornblau Steven, Kantarjian Hagop, Young Ken H, Garcia-Manero Guillermo, Andreeff Michael
机构信息
Department of Leukemia and.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood. 2017 May 4;129(18):2584-2587. doi: 10.1182/blood-2016-11-749903. Epub 2017 Feb 28.
Abstract
摘要
相似文献
1
More than 1 abnormality is a dominant characteristic of pure erythroid leukemia.超过一种异常是纯红细胞白血病的主要特征。
Blood. 2017 May 4;129(18):2584-2587. doi: 10.1182/blood-2016-11-749903. Epub 2017 Feb 28.
2
Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.细胞毒性治疗后发生的纯红细胞白血病中 TP53 改变的差异特征。
Leuk Res. 2022 Jul;118:106860. doi: 10.1016/j.leukres.2022.106860. Epub 2022 May 17.
3
An unusual case of pure erythroid leukemia with normal karyotype and NPM1 mutation.核型正常伴 NPM1 突变的纯红细胞白血病 1 例
J Hematop. 2024 Sep;17(3):163-166. doi: 10.1007/s12308-024-00588-5. Epub 2024 Jul 19.
4
Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.根据世界卫生组织（WHO）新分类法重新审视前M6a型急性红白血病的基因突变与预后
Blood Cancer J. 2017 Aug 25;7(8):e594. doi: 10.1038/bcj.2017.68.
5
Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.使用靶向二代测序对急性红系白血病（M6-AML）进行分子特征分析。
Leukemia. 2016 Apr;30(4):966-70. doi: 10.1038/leu.2015.198. Epub 2015 Jul 23.
6
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.急性红系白血病（AEL）可根据细胞遗传学和分子遗传学特征分为不同的预后亚组。
Leukemia. 2013 Sep;27(9):1940-3. doi: 10.1038/leu.2013.144. Epub 2013 May 7.
7
Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.成人急性淋巴细胞白血病诊断时TP53基因的突变不影响血液学缓解的获得，但与早期复发及极低的生存率相关。
Haematologica. 2016 Jun;101(6):e245-8. doi: 10.3324/haematol.2015.137059. Epub 2016 Mar 18.
8
[The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases].[急性红系白血病的预后及细胞遗传学特征：55例报告]
Zhonghua Nei Ke Za Zhi. 2006 Sep;45(9):738-40.
9
Acute leukaemia with a pure erythroid phenotype: under-recognized morphological and cytogenetic signatures associated universally with primary refractory disease and a dismal clinical outcome.具有纯红系表型的急性白血病：未被充分认识的形态学和细胞遗传学特征，普遍与原发性难治性疾病及不良临床结局相关。
Histopathology. 2017 Aug;71(2):316-321. doi: 10.1111/his.13207. Epub 2017 May 5.
10
TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.从不吸烟的口腔舌鳞状细胞癌中的TP53和CDKN2a突变
Laryngoscope. 2014 Jul;124(7):E267-73. doi: 10.1002/lary.24595. Epub 2014 Feb 20.
引用本文的文献
1
Could Old-School Erythroleukaemia be Back in Style Thanks to ?老派红白血病会因……而再度流行吗？
EJHaem. 2025 Jul 22;6(4):e1106. doi: 10.1002/jha2.1106. eCollection 2025 Aug.
2
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.以红系为主的骨髓增生异常肿瘤表现出独特的基因组格局，在接受基于维奈克拉的治疗后预后较差。
Leukemia. 2025 Jul 21. doi: 10.1038/s41375-025-02711-6.
3
De novo pure erythroid leukemia with rapid progression harboring EZH2 and TP53 frameshift mutations: A case Report.携带EZH2和TP53移码突变且进展迅速的原发性纯红细胞白血病：一例报告
Medicine (Baltimore). 2025 May 9;104(19):e39766. doi: 10.1097/MD.0000000000039766.
4
Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis.阿扎胞苷、维奈克拉和玛格罗利单抗用于新诊断及复发难治性急性髓系白血病：1b/2期研究及相关分析
Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-25-0229.
5
An unusual case of pure erythroid leukemia with normal karyotype and NPM1 mutation.核型正常伴 NPM1 突变的纯红细胞白血病 1 例
J Hematop. 2024 Sep;17(3):163-166. doi: 10.1007/s12308-024-00588-5. Epub 2024 Jul 19.
6
A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.伴有 MDS 相关改变的 AML 的真实世界临床结局分析：ICC 与 WHO-HAEM5 标准的比较。
Blood Adv. 2024 Apr 9;8(7):1760-1771. doi: 10.1182/bloodadvances.2023011869.
7
Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study.美国纯（急性）红白血病的生存率：一项基于监测、流行病学和最终结果（SEER）数据库的研究
Cancers (Basel). 2023 Aug 3;15(15):3941. doi: 10.3390/cancers15153941.
8
TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.TP53 突变的骨髓增生异常综合征和急性髓系白血病。
Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023038. doi: 10.4084/MJHID.2023.038. eCollection 2023.
9
Erythroleukemia: Classification.红白血病：分类
EJHaem. 2023 Mar 17;4(2):450-453. doi: 10.1002/jha2.676. eCollection 2023 May.
10
Emerging bone marrow failure syndromes- new pieces to an unsolved puzzle.新出现的骨髓衰竭综合征——未解谜题的新碎片。
Front Oncol. 2023 Apr 6;13:1128533. doi: 10.3389/fonc.2023.1128533. eCollection 2023.
本文引用的文献
1
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
2
p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.p53基因敲除与增强的NrasG12D信号协同作用，在急性髓系白血病中转化巨核细胞-红系祖细胞。
Blood. 2017 Jan 19;129(3):358-370. doi: 10.1182/blood-2016-06-719237. Epub 2016 Nov 4.
3
Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.CLIA认证实验室中基于下一代测序的血液肿瘤突变分析的分析验证原则。
Expert Rev Mol Diagn. 2016;16(4):461-72. doi: 10.1586/14737159.2016.1142374. Epub 2016 Feb 15.
4
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.治疗相关的骨髓增生异常综合征和急性髓系白血病中的TP53突变特征与原发性疾病相似。
J Hematol Oncol. 2015 May 8;8:45. doi: 10.1186/s13045-015-0139-z.
5
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.通过下一代测序技术对治疗相关骨髓增生异常综合征和急性髓系白血病进行突变分析，并与初发性疾病进行比较。
Leuk Res. 2015 Mar;39(3):348-54. doi: 10.1016/j.leukres.2014.12.006. Epub 2014 Dec 20.
6
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.TP53突变在治疗相关急性髓系白血病的起源与演变中的作用
Nature. 2015 Feb 26;518(7540):552-555. doi: 10.1038/nature13968. Epub 2014 Dec 8.
7
Clinical and biological implications of driver mutations in myelodysplastic syndromes.骨髓增生异常综合征中驱动突变的临床和生物学意义。
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.
8
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.急性红系白血病（AEL）可根据细胞遗传学和分子遗传学特征分为不同的预后亚组。
Leukemia. 2013 Sep;27(9):1940-3. doi: 10.1038/leu.2013.144. Epub 2013 May 7.
9
Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.纯红细胞白血病：采用 2008 年世界卫生组织分类对该实体的再评估。
Mod Pathol. 2011 Mar;24(3):375-83. doi: 10.1038/modpathol.2010.194. Epub 2010 Nov 19.
10
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.成人急性红白血病：单中心 91 例分析。
Leukemia. 2009 Dec;23(12):2275-80. doi: 10.1038/leu.2009.181. Epub 2009 Sep 10.
Zotero 插件